Premium
Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
Author(s) -
Katzka D A,
Loftus E V,
Camilleri M
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.77
Subject(s) - irritable bowel syndrome , medicine , gastroenterology , eosinophilic esophagitis , gerd , gastroparesis , diarrhea , inflammatory bowel disease , disease , ulcerative colitis , gastrointestinal disease , reflux , gastric emptying , stomach
Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes. Clinical Pharmacology & Therapeutics (2012); 92 3, 306–320. doi: 10.1038/clpt.2012.77